Correlation Engine 2.0
Clear Search sequence regions


As part of a project aimed at the identification of a series of small, orally available antagonists for the hNK(2) receptor, starting from one of our capped dipeptide libraries, we succeeded in the chemical optimization of the first identified leads, finally producing a class of molecules with significant activity in our animal model after iv administration. We herein report the results of further chemical modifications made to reduce the overall peptide character of this series and the consequent improvement of their in vivo antagonist activity. The present work identified 6-methylbenzo[b]thiophene-2-carboxylic acid (1-[(S)-1-benzyl-4-[4-(tetrahydropyran-4-ylmethyl)piperazin-1-yl]butylcarbamoyl]cyclopentyl)amide (10i), endowed with subnanomolar potency in all the in vitro tests and being highly potent and of long duration upon in vivo testing after both iv and id dosing.

Citation

Daniela Fattori, Marina Porcelloni, Piero D'Andrea, Rose-Marie Catalioto, Alessandro Ettorre, Sandro Giuliani, Elena Marastoni, Sandro Mauro, Stefania Meini, Cristina Rossi, Maria Altamura, Carlo A Maggi. Structure-activity relationships of 6-methyl-benzo[b]thiophene-2-carboxylic acid (1-[(S)-1-benzyl-4-[4-(tetrahydropyran-4-ylmethyl)piperazin-1-yl]butylcarbamoyl]cyclopentyl)amide, potent antagonist of the neurokinin-2 receptor. Journal of medicinal chemistry. 2010 May 27;53(10):4148-65

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 20408549

View Full Text